

Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis

This supplement to *The American Journal of Managed Care* reviews the clinical and economic burden of multiple sclerosis and summarizes the efficacy and safety of natalizumab. The impact of natalizumab on clinical and economic outcomes is discussed. The role of natalizumab in clinical practice is outlined, with emphasis on selection of appropriate patients for treatment.

■ Faculty

David W. Brandes, MS, MD, FAAN

Hope Neurology
Knoxville, Tennessee
Assistant Clinical Professor, Neurology
University of California, Los Angeles
Los Angeles, California

Patricia K. Coyle, MD

Professor and Acting Chair
Department of Neurology
Stony Brook University Medical Center
and Stony Brook MS Comprehensive Care Center
Stony Brook, New York

John Foley, MD

Director
Rocky Mountain Multiple Sclerosis Clinic
Rocky Mountain Neurological Associates
Salt Lake City, Utah

Michael W. Pill, PharmD

President
Gemini Healthcare, LLC
Westbrook, Connecticut

Fadia T. Shaya, PhD, MPH

Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ Faculty Disclosures

These faculty report relationships with the following organizations:

David W. Brandes, MS, MD, FAAN

Consultant/advisory board/honoraria/lectureship:

Bayer
Biogen Idec
EMD Serono
Teva

Patricia K. Coyle, MD

Board membership:

Bayer
Novartis

Consultant/advisory board:

Acorda
Bayer
Biogen Idec
EMD Serono
Pfizer
sanofi-aventis
Teva

Grants:

Novartis
sanofi-aventis

Honoraria/lectureship:

Bayer
Biogen Idec
EMD Serono
Novartis
Pfizer
sanofi-aventis
Teva

John Foley, MD

Advisory board:

Biogen Idec

Honoraria/lectureship:

Biogen Idec
Genentech
Teva

Michael W. Pill, PharmD, and **Fadia T. Shaya, PhD, MPH**, have nothing to disclose.

Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis

This supplement was supported by **Biogen Idec Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.